- Home
- SISI vs QNRX Comparison
SISI vs QNRX Comparison
Compare SISI & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SISI
- QNRX
- Stock Information
- Founded
- SISI 1997
- QNRX 2018
- Country
- SISI China
- QNRX United States
- Employees
- SISI N/A
- QNRX N/A
- Industry
- SISI Medicinal Chemicals and Botanical Products
- QNRX Medical/Dental Instruments
- Sector
- SISI Health Care
- QNRX Health Care
- Exchange
- SISI Nasdaq
- QNRX Nasdaq
- Market Cap
- SISI 5.6M
- QNRX 4.8M
- IPO Year
- SISI 2016
- QNRX N/A
- Fundamental
- Price
- SISI $5.60
- QNRX $7.59
- Analyst Decision
- SISI
- QNRX
- Analyst Count
- SISI 0
- QNRX 0
- Target Price
- SISI N/A
- QNRX N/A
- AVG Volume (30 Days)
- SISI 97.6K
- QNRX 130.9K
- Earning Date
- SISI 11-13-2025
- QNRX 11-06-2025
- Dividend Yield
- SISI N/A
- QNRX N/A
- EPS Growth
- SISI N/A
- QNRX N/A
- EPS
- SISI N/A
- QNRX N/A
- Revenue
- SISI $9,601,324.00
- QNRX N/A
- Revenue This Year
- SISI N/A
- QNRX N/A
- Revenue Next Year
- SISI N/A
- QNRX N/A
- P/E Ratio
- SISI N/A
- QNRX N/A
- Revenue Growth
- SISI 1133.26
- QNRX N/A
- 52 Week Low
- SISI $1.00
- QNRX $5.01
- 52 Week High
- SISI $271.50
- QNRX $54.95
- Technical
- Relative Strength Index (RSI)
- SISI 43.37
- QNRX 52.72
- Support Level
- SISI $5.42
- QNRX $6.93
- Resistance Level
- SISI $6.27
- QNRX $7.41
- Average True Range (ATR)
- SISI 0.61
- QNRX 0.49
- MACD
- SISI -0.04
- QNRX 0.01
- Stochastic Oscillator
- SISI 12.49
- QNRX 48.42
About SISI Shineco Inc.
Shineco Inc aims to care for a healthy life and improve the quality of life by providing safe, efficient, and high-quality health products and services to society. The company has researched and developed various vitro diagnostic reagents and related medical devices to date, and it also produces and sells healthy and nutritious food.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.